Researchers at Washington University School of Medicine found a genetically-engineered protein – APT102 – was more effective than clopidogrel at preventing blood clots from reforming in dogs after a heart attack and reduced the risk of bleeding.
After a heart attack patients areusually given drugs including aspirin and clopidogrel to prevent further clots from forming. However, this can increase the risk of internal bleeding.
The study also found the protein reduced the damage caused to the heart tissue caused by the heart attack.
